Table 2.

Tumor response to afatinib

	Treatment line
	Any		First
	All patients (N = 67)	Acquired T790M (n = 49)	All patients (n = 54)	Acquired T790M (n = 36)
Response, n (%) [95% CI]
Overall	62 (92.5)	46 (93.9)	50 (92.6)	34 (94.5)
Complete	13 (19.4) [9.9–28.8]	13 (26.5) [14.2–38.9]	10 (18.5) [8.2–28.9]	10 (27.8) [13.1–42.4]
Partial	49 (73.1) [62.5–83.7]	33 (67.3) [54.2–80.5]	40 (74.1) [62.4–85.8]	24 (66.7) [51.3–82.1]
Stable disease	2 (3.0) [−1.1–7.0]	2 (4.1) [−1.5–9.6]	1 (1.9) [−1.7–5.4]	1 (2.8) [−2.6–8.1]
Duration, n (%) [95% CI]
≥6 months	59 (88.1) [80.3–95.8]	44 (89.8) [81.3–98.3]	47 (87.0) [78.1–96.0]	32 (88.9) [78.6–99.1]
≥12 months	34 (50.7) [38.8–62.7]	24 (49.0) [35.0–63.0]	29 (53.7) [40.4–67.0]	19 (52.8) [36.5–69.1]
≥18 months	15 (22.4) [12.4–32.4]	13 (26.5) [14.2–38.9]	12 (22.2) [11.1–33.3]	10 (27.8) [13.1–42.4]
≥24 months	5 (7.5) [1.1–13.8]	5 (10.2) [1.7–18.7]	4 (7.4) [0.4–14.4]	4 (11.1) [0.8–21.4]